VIVS
VivoSim Labs, INC.Company Information
- Company Name
- VivoSim Labs, INC.
- CIK
- CIK0001497253
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- VIVS: Nasdaq
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- VIVS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-31
- Last sale
- 2025-11-17
- Shares purchased (TTM)
- 10,000
- Shares sold (TTM)
- 3,266
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 84,792
- Shares outstanding
- 5,239,462
- Ownership
- 1.62%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -15.15%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 5 | 4 | 7 | 9 | 11 | 1 | 3 | 6 | 3 | 5 | 8 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | - | - | - | - | - | 0 | 0 | 1 | 0 | 0 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Current | 3 | 7 | 6 | 8 | 10 | 12 | 2 | 5 | 7 | 4 | 6 | 8 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Escrow Deposit | 1 | 0 | 0 | 1 | 1 | 1 | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets | - | 0 | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Assets | 4 | 7 | 7 | 10 | 12 | 15 | 4 | 7 | 9 | 6 | 9 | 11 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities Current | 2 | 3 | 2 | 2 | 2 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities | 6 | 8 | 3 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 355 | 355 | 355 | 355 | 355 | 353 | 349 | 349 | 350 | 343 | 343 | 341 | ||||||
| Retained Earnings Accumulated Deficit | -357 | -356 | -350 | -348 | -345 | -342 | -349 | -346 | -343 | -340 | -337 | -333 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | 0 | - | 0 | 0 | 0 | ||||||
| Treasury Stock Common Value | - | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | -2 | -1 | 4 | 7 | 10 | 10 | 0 | 4 | 7 | 4 | 6 | 8 | ||||||
| Liabilities And Stockholders Equity | 4 | 7 | 7 | 10 | 12 | 15 | 4 | 7 | 9 | 6 | 9 | 11 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Treasury Stock Common Shares | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVivoSim Labs, INC. (VIVS) — SEC Financial Statements & Analysis
VivoSim Labs, INC. (VIVS) is a biological products, (no diagnostic substances) company, incorporated in DE. VivoSim Labs, INC. trades on Nasdaq as: VIVS. VivoSim Labs, INC. (VIVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, VivoSim Labs, INC. carries a market cap of $5.61M, a P/E ratio of -0.45x, a P/B ratio of -2.39x, a P/S ratio of 50.06x, an enterprise value of $3.94M, and an EV/EBITDA multiple of -0.35x. On profitability, it posts an operating margin of -10116.96%, a net margin of -11016.07%, a Return on Equity (ROE) of -343.10%, a Return on Assets (ROA) of -155.93%, and a Return on Invested Capital (ROIC) of -2705.59%. Per share, it reports EPS of $-2.35, diluted EPS of $-2.35, free cash flow per share of $-1.93, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -21.13% year-over-year, net income growth of 520.94% year-over-year, and EPS growth of 196.72% year-over-year. On the balance sheet, it maintains a current ratio of 1.70x, a quick ratio of 1.43x, working capital of $1.33M, a debt-to-equity ratio of -2.64x, a debt ratio of 1.61, an interest coverage ratio of -944.25x, free cash flow of $-10.12M (TTM), and net debt of $-1.67M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.61M
- P/E TTM
- -0.45x
- EPS TTM
- $-2.35
- P/B TTM
- -2.39x
- ROE TTM
- -343.10%
- ROA TTM
- -155.93%
- Debt To Equity
- -2.64x
- Free Cash Flow TTM
- $-10.12M
- Net Revenue TTM Growth 1Y
- -21.13%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is VivoSim Labs, INC. in?
VivoSim Labs, INC. (VIVS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does VIVS trade on?
VivoSim Labs, INC. (VIVS) trades on the Nasdaq.
Where is VivoSim Labs, INC. incorporated?
VivoSim Labs, INC. is incorporated in DE.
When was VivoSim Labs, INC. (VIVS)'s most recent SEC filing?
VivoSim Labs, INC. (VIVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is VIVS's market cap?
VivoSim Labs, INC. (VIVS) has a market capitalization of $5.61M as of 2026-06-30.
What is VIVS's EPS (earnings per share)?
VivoSim Labs, INC. (VIVS)'s trailing twelve month EPS is $-2.35 as of 2026-06-30.
What is VIVS's ROE (return on equity)?
VivoSim Labs, INC. (VIVS)'s trailing twelve month Return on Equity (ROE) is -343.10% as of 2026-06-30.
What is VIVS's ROA (return on assets)?
VivoSim Labs, INC. (VIVS)'s trailing twelve month Return on Assets (ROA) is -155.93% as of 2026-06-30.
What is VIVS's ROIC (return on invested capital)?
VivoSim Labs, INC. (VIVS)'s trailing twelve month Return on Invested Capital (ROIC) is -2705.59% as of 2025-09-30.
What is VIVS's EV/EBITDA?
VivoSim Labs, INC. (VIVS)'s trailing twelve month EV/EBITDA is -0.35x as of 2026-06-30.